Incyte and CMS collaborate for povorcitinib in Mainland China, Hong Kong, Macau, Taiwan and SEA [Seeking Alpha]
Incyte Corporation (INCY)
Last incyte corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
incyte.com/ir/investor-overview.aspx
Company Research
Source: Seeking Alpha
Agreement is for the development and commercialization of povorcitinib, a selective oral JAK1 inhibitor, to research, develop, register and commercialize the product in Mainland China, Hong Kong, Macao, Taiwan Region and eleven Southeast Asian countries and a non-exclusive license to manufacture the product in CMS' Territory. Under the terms of the agreement, CMS will make an upfront payment to Incyte and Incyte is eligible to receive additional potential development and commercial milestones and royalties on net sales of the licensed product in CMS' territory. CMS will receive an exclusive license to develop and commercialize and a non-exclusive license to manufacture povorcitinib in autoimmune and inflammatory dermatologic diseases for patients in mainland China, Hong Kong, Macau, Taiwan and certain countries in Southeast Asia. Recommended For You More Trending News Recommended For You More Trending News About INCY Stock Related Stocks Trending Analysis Trending
Show less
Read more
Impact Snapshot
Event Time:
INCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INCY alerts
High impacting Incyte Corporation news events
Weekly update
A roundup of the hottest topics
INCY
News
- Repare Therapeutics appoints Steven Stein to its board of directors [Seeking Alpha]Seeking Alpha
- Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors [Yahoo! Finance]Yahoo! Finance
- Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade) [Seeking Alpha]Seeking Alpha
- Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX [Yahoo! Finance]Yahoo! Finance
- Incyte Co. (NASDAQ: INCY) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $92.00 to $84.00. They now have an "outperform" rating on the stock.MarketBeat
INCY
Earnings
- 2/13/24 - Beat
INCY
Sec Filings
- 4/29/24 - Form ARS
- 4/29/24 - Form DEFA14A
- 4/29/24 - Form DEF
- INCY's page on the SEC website